Fortaco Group to be Acquired by One Equity Partners
8.7.2022 14:00:00 EEST | Business Wire | Press release
Funds managed by CapMan Buyout have agreed to sell their holdings in Fortaco Group, the leading strategic partner to the heavy off-highway equipment and marine industries offering technology, vehicle cabins, steel fabrications, and assemblies to global OEMs, to private equity firm One Equity Partners.
As the new owner, One Equity Partners will empower the further development of the current and new offerings of Fortaco, including areas to strengthen value creation to customers and to provide the means for further international expansion.
“We are very honored to become a member of the One Equity Partners family. I want to express my sincere thanks to all our global customers, business partners, and the Fortaco team for the highly qualified performance we reached together. With One Equity Partners, we are looking forward to realizing the full potential of Fortaco as the leading business partner of technology, vehicle cabins, steel fabrications and assemblies. In addition, I want to thank CapMan as the owner and the Board of Directors for their support and trust,” says Lars Hellberg, President & CEO of Fortaco Group.
“We look forward to partnering with Fortaco CEO Lars Hellberg and his team, applying our industrial sector expertise to support Fortaco in broadening and deepening its offerings in current markets and expanding into new end markets where we believe the Company is well-positioned for success,” said Johann-Melchior von Peter, Senior Managing Director at One Equity Partners. “We see ample opportunity for Fortaco to leverage its global manufacturing and sourcing footprint and extend its value to clients by helping them improve their operational efficiency,” adds Marc Lindhorst, Principal at One Equity Partners.
Under the ownership of CapMan, Fortaco has grown and become a market-leading, premium industrial company. Fortaco has factories across seven European countries, in addition to a joint venture with Tata AutoComp in India. Fortaco also has a large portfolio of global customers in different industry segments, and the company’s turnover and profitability have developed very favorably in recent years.
“CapMan was one of the initiators in the formation of Fortaco Group ten years ago. We have provided continuous strategic support over the company’s many development phases towards the market leader it is today with ambitious growth prospects. I would like to thank Fortaco’s management team and employees for excellent co-operation over the years. The company is now well-positioned to continue its growth journey with One Equity Partners as the new owner,” says Anders Björkell, partner at CapMan Buyout.
Closing of the transaction is expected in the second half of 2022 and is subject to regulatory approvals and customary closing conditions.
Fortaco
Fortaco is the leading brand-independent strategic partner to the heavy off-highway equipment and marine industries offering technology, vehicle cabins, steel fabrications and assemblies. Fortaco Group has operations in multiple European and Asian business sites and technology hubs, which are supporting the global customers.
One Equity Partners
One Equity Partners is a middle market private equity firm focused on transformative combinations within the industrial, healthcare and technology sectors in North America and Europe. The firm was founded in 2001 and spun out of JP Morgan in 2015 to become an independent partnership. One Equity Partners has completed more than 300 transactions worldwide with offices in New York, Chicago, Frankfurt and Amsterdam.
CapMan
CapMan is a leading Nordic private assets manager and investor with an active approach to value creation. As one of the private equity pioneers in the Nordics they have built value in unlisted businesses, real estate, and infrastructure for over three decades. With over €4.7 billion in assets under management, their objective is to provide attractive returns and innovative solutions to investors.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220708005059/en/
Contact information
For more information
Lars Hellberg
+358 40 572 9488
lars.hellberg@fortacogroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
